Details of Disease

General Information of Disease (ID: DISK2MZ2)

• Disease Name: Bacterial vaginosis
• Synonyms: BV
• Disease Class: MF3A: Vaginal discharge
• Definition: Infection caused by bacterial overgrowth in the vagina. Most affected women are asymptomatic. When symptoms occur, they include foul-smelling vaginal discharge, vaginal itching, and burning. Risk factors include sexual activity with multiple partners and the use of vaginal douches and intrauterine devices. Up to a third of cases resolve without treatment. Antibiotic treatment is recommended when symptoms are present and for women that are pregnant at the time of infection.
• Disease Hierarchy:
  DISZAC8Z: Bifidobacteriales infectious disease
  DISVXFB7: Vaginal infection
  DISK2MZ2: Bacterial vaginosis
• ICD Code:
  ICD-11: ICD-11: MF3A
  ICD-10: ICD-10: N89.8
  Expand ICD-11: 'MF3A
  Expand ICD-10: 'N89.8
• Disease Identifiers:
  MONDO ID: MONDO_0005316
  MESH ID: D016585
  UMLS CUI: C0085166
  MedGen ID: 43118
  SNOMED CT ID: 419760006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Astodrimer	DM2GSA5	Approved	NA	[1]
Clindamycin	DM15HL8	Approved	Small molecular drug	[2]
Metronidazole	DMTIVEN	Approved	Small molecular drug	[3]
Secnidazole	DMJ18YL	Approved	Small molecular drug	[4]
Tindamax	DM3OWT4	Approved	Small molecular drug	[5]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DARE-BV1	DM1C95G	Phase 3	Small molecular drug	[6]
ABV3	DME55A8	Phase 2	Small molecular drug	[7]
TOL-463	DM8VV80	Phase 2	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CTNS	TT1W2ZS	Limited	Altered Expression	[9]
HCN1	TTNB6UQ	Limited	Altered Expression	[10]
IL36G	TT8SLDN	Limited	Altered Expression	[11]
NODAL	TTK2O1Q	Limited	Genetic Variation	[12]
TIRAP	TTKU0LS	Limited	Biomarker	[13]
GLA	TTIS03D	Strong	Genetic Variation	[14]
LYZ	TTAOZBW	Strong	Biomarker	[15]

This Disease Is Related to 14 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DEFA1	OT5N1B9B	Limited	Altered Expression	[16]
DEFA3	OTO3N8E1	Limited	Altered Expression	[16]
DEFA5	OT95CBQ9	Limited	Biomarker	[17]
DEFB103B	OT8RWY64	Limited	Altered Expression	[18]
HM13	OTGEO1LP	Limited	Biomarker	[19]
IVD	OT8JFXUQ	Limited	Genetic Variation	[20]
RPTN	OTOAA25U	Limited	Biomarker	[21]
SIGIRR	OTNC3XFD	Limited	Biomarker	[22]
CLSTN1	OTQN35G2	Strong	Biomarker	[23]
CST1	OTE4I83Q	Strong	Biomarker	[23]
CST2	OTRKRW50	Strong	Biomarker	[23]
CST4	OTXXM8EH	Strong	Biomarker	[24]
MAX	OTKZ0YKM	Strong	Biomarker	[25]
PI3	OT47MTC3	Strong	Biomarker	[26]

References

• [1] Clinical pipeline report, company report or official report of Starpharma.
• [2] Clindamycin FDA Label
• [3] Metronidazole FDA Label
• [4] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [5] Tinidazole. 2021 Mar 17. Drugs and Lactation Database (LactMed?) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006C.
• [6] ClinicalTrials.gov (NCT04370548) DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE). U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Hennepin Life Sciences.
• [8] ClinicalTrials.gov (NCT02866227) TOL-463 Phase 2 Study for Vaginitis. U.S. National Institutes of Health.
• [9] In vitro correction of disorders of lysosomal transport by microvesicles derived from baculovirus-infected Spodoptera cells.Mol Genet Metab. 2013 May;109(1):77-85. doi: 10.1016/j.ymgme.2013.01.014. Epub 2013 Feb 4.
• [10] Contribution of large-sized primary sensory neuronal sensitization to mechanical allodynia by upregulation of hyperpolarization-activated cyclic nucleotide gated channels via cyclooxygenase 1 cascade.Neuropharmacology. 2017 Feb;113(Pt A):217-230. doi: 10.1016/j.neuropharm.2016.10.012. Epub 2016 Oct 12.
• [11] Interleukin-36 Is Elevated in Cervicovaginal Epithelial Cells in Women With Bacterial Vaginosis and In Vitro After Infection With Microbes Associated With Bacterial Vaginosis.J Infect Dis. 2020 Mar 2;221(6):983-988. doi: 10.1093/infdis/jiz514.
• [12] Evidence of a gene-environment interaction of NODAL variants and inflammation in preterm birth.J Perinatol. 2018 May;38(5):482-488. doi: 10.1038/s41372-018-0073-3. Epub 2018 Feb 16.
• [13] Cross-sectional analysis of Toll-like receptor variants and bacterial vaginosis in African-American women with pelvic inflammatory disease.Sex Transm Infect. 2014 Nov;90(7):563-6. doi: 10.1136/sextrans-2014-051524. Epub 2014 May 21.
• [14] Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial.Benef Microbes. 2019 Feb 8;10(1):19-26. doi: 10.3920/BM2018.0075. Epub 2018 Dec 10.
• [15] The Effect of Lysozyme on Reducing Biofilms by Staphylococcus aureus, Pseudomonas aeruginosa, and Gardnerella vaginalis: An In Vitro Examination.Microb Drug Resist. 2018 May;24(4):353-358. doi: 10.1089/mdr.2016.0303. Epub 2017 Sep 18.
• [16] Midpregnancy vaginal fluid defensins, bacterial vaginosis, and risk of preterm delivery.Obstet Gynecol. 2008 Sep;112(3):524-31. doi: 10.1097/AOG.0b013e318184209b.
• [17] Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis.Int J Gynaecol Obstet. 2008 Oct;103(1):50-4. doi: 10.1016/j.ijgo.2008.05.020. Epub 2008 Jul 16.
• [18] Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection.PLoS One. 2019 Apr 26;14(4):e0216049. doi: 10.1371/journal.pone.0216049. eCollection 2019.
• [19] Prospective Evaluation of Molecular Assays for Diagnosis of Vaginitis.J Clin Microbiol. 2019 Dec 23;58(1):e01264-19. doi: 10.1128/JCM.01264-19. Print 2019 Dec 23.
• [20] Increased richness and diversity of the vaginal microbiota and spontaneous preterm birth.Microbiome. 2018 Jun 28;6(1):117. doi: 10.1186/s40168-018-0502-8.
• [21] The vaginal microbiome amplifies sex hormone-associated cyclic changes in cervicovaginal inflammation and epithelial barrier disruption.Am J Reprod Immunol. 2018 Jul;80(1):e12863. doi: 10.1111/aji.12863. Epub 2018 Apr 30.
• [22] Gene polymorphisms of Toll-like and related recognition receptors in relation to the vaginal carriage of Gardnerella vaginalis and Atopobium vaginae.J Reprod Immunol. 2009 Jan;79(2):163-73. doi: 10.1016/j.jri.2008.10.006. Epub 2009 Feb 6.
• [23] Factors associated with the composition and diversity of the cervical microbiota of reproductive-age Black South African women: a retrospective cross-sectional study.PeerJ. 2019 Aug 15;7:e7488. doi: 10.7717/peerj.7488. eCollection 2019.
• [24] Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection.Sci Rep. 2017 Aug 31;7(1):10200. doi: 10.1038/s41598-017-09842-6.
• [25] Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women.Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):39-44. doi: 10.1007/s10096-019-03694-w. Epub 2019 Sep 9.
• [26] Anti-inflammatory Elafin in human fetal membranes.J Perinat Med. 2017 Feb 1;45(2):237-244. doi: 10.1515/jpm-2016-0139.